O

Orion Oyj
OMXH:ORNBV

Watchlist Manager
Orion Oyj
OMXH:ORNBV
Watchlist
Price: 42.44 EUR -0.79% Market Closed
Market Cap: 6B EUR
Have any thoughts about
Orion Oyj?
Write Note

Orion Oyj
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Orion Oyj
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
O
Orion Oyj
OMXH:ORNBV
Cash from Investing Activities
-€78m
CAGR 3-Years
-20%
CAGR 5-Years
-5%
CAGR 10-Years
-1%
H
Herantis Pharma Oyj
OMXH:HRTIS
Cash from Investing Activities
-€473.9k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Orion Oyj
Glance View

Market Cap
6B EUR
Industry
Pharmaceuticals

Orion Oyj, a stalwart in the pharmaceutical industry, has carved out a significant niche for itself since its inception in Finland. The company was founded in 1917, and over the years, it has evolved into a crucial player in the global medical landscape. As a fully integrated pharmaceutical entity, Orion’s operations encompass everything from research and development to manufacturing and distribution. Its primary areas of focus include the development of therapies for central nervous system disorders, oncology, and respiratory diseases, as well as a selection of veterinary medicines and active pharmaceutical ingredients (APIs). This comprehensive approach enables Orion to maintain control over the entire drug production pipeline, ensuring quality and innovation are at the forefront of its mission. Orion's business strategy revolves around a robust combination of proprietary innovations and strategic partnerships. The company invests heavily in R&D, dedicating a substantial portion of its revenue to discovering and developing new drugs. By doing so, it fortifies its product pipeline, ensuring a steady influx of new offerings that cater to unmet medical needs, fostering a competitive edge in the market. Additionally, Orion supplements its earnings through collaborations with other pharmaceutical giants, expanding its market reach and sharing resources to mitigate risks associated with the costly drug development process. Through this dual approach of in-house excellence and collaborative ventures, Orion Oyj effectively sustains its financial health, continually fueling its growth and ensuring it remains a formidable force in the international pharmaceutical arena.

ORNBV Intrinsic Value
53.94 EUR
Undervaluation 21%
Intrinsic Value
Price
O

See Also

What is Orion Oyj's Cash from Investing Activities?
Cash from Investing Activities
-78m EUR

Based on the financial report for Jun 30, 2024, Orion Oyj's Cash from Investing Activities amounts to -78m EUR.

What is Orion Oyj's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
-1%

Over the last year, the Cash from Investing Activities growth was 28%. The average annual Cash from Investing Activities growth rates for Orion Oyj have been -20% over the past three years , -5% over the past five years , and -1% over the past ten years .

Back to Top